• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Inato Launches AI-Powered Patient Pre-Screening to Reduce Site Burden and Accelerate Enrollment

by Syed Hamza Sohail 01/28/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–       Inato, the leading platform for clinical trial access and inclusivity, today unveiled new capabilities to help research sites efficiently pre-screen patients for trial opportunities.

–       The company’s latest advancement integrates a series of artificial intelligence (AI) models into a unified agent that quickly and securely reviews patient records and assesses eligibility, transforming a historically time-consuming and cumbersome process for sites. 

Inato: Revolutionizing Clinical Trial Access with AI-Driven Solutions

Inato is on a mission to democratize clinical research, ensuring every patient has access to trials regardless of location. By integrating trial planning, site selection, and patient pre-screening into a single AI-powered platform, Inato enhances collaboration among research sites, sponsors, and Contract Research Organizations (CROs). Trusted by leading pharmaceutical companies and utilized by thousands of research sites, Inato streamlines trial operations and improves trial accessibility and representation.

Tackling the Patient Enrollment Challenge

Patient enrollment remains a significant bottleneck in clinical trials, now taking 25% longer than it did five years ago. Factors such as growing trial complexity, increasing trial sizes, and heightened competition for participants threaten to exacerbate this issue. Leveraging advancements in generative AI, Inato addresses these challenges by:

  • Streamlining patient identification and eligibility reviews.
  • Reducing site burden through efficient AI-driven processes.
  • Accelerating trial timelines while maintaining accuracy and compliance.

Transformative AI-Powered Pre-Screening

Inato’s AI-enabled patient pre-screening feature, now available across the United States, significantly optimizes the patient evaluation process without requiring EMR or CTMS integration. Key capabilities include:

  • Assessing patient records against inclusion and exclusion criteria in minutes, with 95% accuracy.
  • Reducing pre-screening times by more than 50%, and up to 90% for early adopters.
  • Empowering site staff to make informed, rapid decisions about patient eligibility.

The platform employs an AI agent to de-identify patient records, identify relevant trials, and evaluate eligibility based on complex criteria. For instance, if a trial requires patients with specific seizure patterns, the AI combines medical reasoning and mathematical analysis to generate a straightforward eligibility assessment in minutes.

Advancing Collaboration and Accessibility

Inato collaborates with trial sponsors and research sites, including organizations like Pantheon Clinical Research, to continually refine and expand its AI capabilities. Current features enable research sites to:

  • Identify relevant trials aligned with their community’s needs.
  • Craft compelling trial applications that highlight their unique capabilities.
  • Leverage AI for advanced pre-screening and feasibility assessments, reducing administrative burden.

Transforming the Future of Clinical Research

“Inato’s advancements in AI reasoning enable sites to identify and review patients at scale, fundamentally transforming patient recruitment,” said Kourosh Davarpanah, Co-founder and CEO of Inato. “This innovation allows sites to offer more trial options to patients, accelerate enrollment, and enhance research access.”

By reducing pre-screening time, simplifying eligibility evaluations, and fostering collaboration, Inato is redefining how clinical trials are conducted—advancing medical research and improving patient access on a global scale.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Clinical Trials

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |